This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing Information (PI), and Summary of Product Characteristics (SmPC) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
2026 Events Coming Soon.
We are currently working on meetings for 2026 and will update this page when we have more details. Please check back again soon.
Please refer to the PRODUODOPA SmPC for further information on adverse events, contraindications and special warnings and precautions for use.
References
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-250316. Date of preparation: October 2025.
